Robert Z. Orlowski

Faculty positions available for #myeloma clinician scientists. Join our @MDAndersonNews #Myeloma Team! mdanderson.org/about-md-ander… Please RT!

#Myeloma Paper of the Day: Case series of elranatamab for relapsed &/or refractory advanced stage AL #amyloidosis finds 100% ORR & 67% CR rate; median time to heme response of 9 days (6-24), translating into cardiac & renal responses at 3-6 months: pubmed.ncbi.nlm.nih.gov/40712156/. #mmsm

#Myeloma Paper of the Day: Study of myeloma patient preferences on clinical decision making concludes that many choose against treatments that improve PFS if they do not positively affect OS and lead to clinical, financial, and/or time toxicities: pubmed.ncbi.nlm.nih.gov/40705989/. #mmsm

#Myeloma Paper of the Day: BCMA-mRNA vaccine encapsulated in LNPs w/ poly(I:C) as TLR3 agonist is internalized by dendritic cells in vitro and leads to BCMA-specific CD8+ CTL and in vivo anti-myeloma response in two mouse myeloma models: pubmed.ncbi.nlm.nih.gov/40700574/. #mmsm

#Myeloma Paper of the Day: Single-center experience of long-term outcomes of AL #amyloidosis patients receiving heart transplant finds 1-, 3-, 5-, and 8-year survival (87%, 83%, 73%, and 67%) not different vs. non-AL patients (92%, 85%, 79%, 68%): pubmed.ncbi.nlm.nih.gov/40687315/. #mmsm

#Myeloma Paper of the Day: Viewpoint piece makes evidence-based arguments for use of primary prophylaxis as a safer and simpler approach compared to preemptive IgG-guided immunoglobulin replacement therapy in pts getting bispecific antibodies: pubmed.ncbi.nlm.nih.gov/40690761/. #mmsm

#Myeloma Paper of the Day: Long-term follow-up of venetoclax monotherapy in previously treated #Waldenström macroglobulinemia shows median PFS 36 mos, median treatment-free survival 43 mos, no BCL2 G101V mutations in 52 CD19-selected samples: pubmed.ncbi.nlm.nih.gov/40674749/. #mmsm

#Myeloma Paper of the Day: Updated follow-up of DREAMM-7 study shows continued superiority of BVd vs. DVd in median OS (NR vs. 41.0 months), PFS2 (NR vs. 33.4 months), MRD-negativity (25% vs. 10%), and duration of response (40.8 vs. 17.8 months): pubmed.ncbi.nlm.nih.gov/40680754/. #mmsm

#Myeloma Paper of the Day: Residual disease assessed w/ whole body MRI per MY-RADS protocol linked to shorter PFS (median 24 vs. 42 months) and OS (median 47 months vs. NE) in newly diagnosed or at first relapse patients undergoing first ASCT: pubmed.ncbi.nlm.nih.gov/40675973/. #mmsm

#Myeloma Paper of the Day: Case series of teclistamab in myeloma patients w/ secondary plasma cell leukemia (#PCL) shows median PFS of only 27 days (responders had PFS of 4.6 months) and none of those with prior BCMA therapy exposure had a response: pubmed.ncbi.nlm.nih.gov/40674710/. #mmsm

#Myeloma Paper of the Day: Del(17p), t(4;14), t(14;16), but not 1q+ are high-risk cytogenetic abnormalities (HRCAs) in primary #PCL; HRCA, elevated LDH, thrombocytopenia have highest OS impact & can create simple algorithm stratifying pPCL patients: pubmed.ncbi.nlm.nih.gov/40660267/. #mmsm

#Myeloma Paper of the Day: Genomic & immune profiling of prognostic groups in IgM gammopathy reveals novel biomarkers beyond MYD88 L265P e.g. CXCR4, KMT2D, ARID1A and EP300 mutations, upregulated genes involved in NF-κB and BCR signaling activation: pubmed.ncbi.nlm.nih.gov/40666506/. #mmsm

Myeloma Paper of the Day, July 15th, Suggested by Robert Orlowski (@Myeloma_Doc) @JoselleCookMD @RahmaWarsameMD @myelomaMD @VincentRK @ADispenzieri oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma…

#Myeloma Paper of the Day: Interleukin-6 is a prognostic biomarker for #POEMS syndrome associated w/ EFS & OS (pts w/ elevated IL-6 had 17-fold increased risk of death vs. those with normal values), along with hypoalbuminemia & a high Wang score: pubmed.ncbi.nlm.nih.gov/40646134/. #mmsm

#Myeloma Paper of the Day: 2021 Global Burden of Disease study data indicate standardized disability-adjusted life years rate for myeloma in China is rising w/ average annual percentage change 4.14% (4.01-4.28%) while most other cancers decreasing: pubmed.ncbi.nlm.nih.gov/40652211/. #mmsm

#Myeloma Paper of the Day: Sequential treatment with two different commercially approved BCMA CAR-T products (ide-cel -> cilta-cel) is both feasible and effective, particularly in patients with prolonged responses to initial BCMA CAR-T therapy: pubmed.ncbi.nlm.nih.gov/40644619/. #mmsm

Myeloma Paper of the Day, July 12th, Suggested by Robert Orlowski (@Myeloma_Doc) oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma @CancerWorldmag

#Myeloma Paper of the Day: Profiling architecture of myeloma in human bone marrow biopsies w/ spatial transcriptomics finds spatially restricted subpopulations of PCs & distinct microenvironments that can vary between patients and spatial locations: pubmed.ncbi.nlm.nih.gov/40643106/. #mmsm

#Myeloma Paper of the Day: BCMA is a highly short-lived protein that undergoes K48-linked polyubiquitylation at plasma membrane & carfilzomib enhances the efficacy of BCMA-directed CAR T cells against both PI-sensitive and refractory myeloma cells: pubmed.ncbi.nlm.nih.gov/40638685/. #mmsm

#Myeloma Paper of the Day: US Myeloma Immunotx Consortium teclistamab data: 54% CRS (1.4% G≥3), 11% ICANS (2.2% G≥3), 42% infxns, 53% ≥PR, 45% ≥VGPR, PFS 5.8 mos, 12-mo OS 61%; BCMA CAR w/in 9 mos, hi dz/ferritin, lymphopenia reduce benefit: pubmed.ncbi.nlm.nih.gov/40629516/. #mmsm

#Myeloma Paper of the Day: Case report of the use of teclistamab for treatment of relapsed/refractory #POEMS syndrome producing a durable biochemical & radiographic remission lasting past drug discontinuation & without any unanticipated toxicities: pubmed.ncbi.nlm.nih.gov/40605704/. #mmsm